Epigenomics AG Stock OTC Markets
Stocks
EPGNF
DE000A37FT41
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.100 USD | +17.89% |
|
-1.82% | -1.82% |
| 04-02 | Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 25-07-22 | Epigenomics AG Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 824K 946K 770K 707K 1.33M 90.09M 1.36M 9.12M 3.56M 44.85M 3.55M 3.47M 154M | P/E 2024 |
-0.29x | P/E 2025 | -2.51x |
|---|---|---|---|---|---|
| Enterprise Value | 11.79M 13.53M 11.01M 10.12M 18.99M 1.29B 19.44M 130M 50.97M 642M 50.72M 49.63M 2.21B | EV / Sales 2024 |
-
| EV / Sales 2025 | 490x |
| Free-Float |
70.75% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +17.89% | ||
| 1 week | -1.82% | ||
| Current month | -1.82% | ||
| 1 month | -1.82% | ||
| 3 months | -1.82% | ||
| 6 months | -1.82% | ||
| Current year | -1.82% |
| 3 years | 0.5 |  | 1.12 |
| 5 years | 0.24 | | 1.76 |
| 10 years | 0.24 | | 8.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frederic Hilke
IRC | Investor Relations Contact | - | - |
| Corporate Officer/Principal | 55 | 2024-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Helge Lubenow
CHM | Chairman | 58 | 2023-02-28 |
Alexander Link
BRD | Director/Board Member | 55 | 2020-05-31 |
Jochen Hummel
BRD | Director/Board Member | 56 | 2024-02-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +17.89% | -1.82% | - | - | 949K | |
| +0.11% | -6.42% | +122.66% | +98.26% | 4.43B | |
| +0.18% | -0.09% | +112.63% | +179.55% | 3.6B | |
| -2.98% | -16.79% | +54.58% | -36.67% | 2.1B | |
| +0.89% | +1.58% | -28.27% | -37.50% | 2.1B | |
| -0.95% | -8.12% | +176.86% | +217.29% | 1.85B | |
| -3.94% | -7.18% | +148.68% | -42.45% | 1.01B | |
| -2.86% | -6.43% | -15.73% | +18.65% | 820M | |
| +1.04% | +1.48% | -39.46% | -14.85% | 497M | |
| -10.56% | -0.87% | -12.05% | - | 453M | |
| Average | -0.12% | -5.00% | +57.77% | +47.79% | 1.87B | |
| Weighted average by Cap. | -0.92% | -4.93% | +85.63% | +78.82% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 24K 27.53K 22.4K 20.59K 38.64K 2.62M 39.56K 265K 104K 1.31M 103K 101K 4.5M |
| Net income | -3.35M -3.84M -3.13M -2.88M -5.4M -366M -5.53M -37.07M -14.49M -182M -14.42M -14.11M -628M | -314K -360K -293K -269K -506K -34.32M -518K -3.47M -1.36M -17.09M -1.35M -1.32M -58.85M |
| Net Debt | 10.46M 11.99M 9.76M 8.97M 16.83M 1.14B 17.23M 116M 45.19M 569M 44.97M 44.01M 1.96B | 10.97M 12.58M 10.24M 9.41M 17.66M 1.2B 18.08M 121M 47.4M 597M 47.18M 46.16M 2.06B |
Employees
3
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ECX Stock
- EPGNF Stock
Select your edition
All financial news and data tailored to specific country editions
